Airfinity launches Influenza and RSV Commercial solutions

Posted on Jul 6, 2022

Building on its pioneering work in COVID-19 intelligence, Airfinity's Commercial offering, demand models, visualisations, and in-depth intelligence reports have been extended into two new disease areas. Users can now subscribe to proprietary insight into the vaccine market for approved and pipeline candidates within both Influenza and RSV.

The solution includes platform access, quarterly newsletters and reports, and direct analyst support. Expect expert commentary and in-depth analysis across burden of disease, treatment landscapes, vaccine pipeline, pricing analysis and more.

With Airfinity's Commercial product, you will have access to:

Predictive indicators to anticipate market shifts and highlight emerging opportunities

Market access analysis to help you focus on the right sales channels

Real-time demand forecasts and on-going supply deals to highlight unmet need

Extensive datasets such as procurement tenders, supply deals, vaccination rates, etc. to provide a thorough and well-rounded view of the current and future market

To learn more about the new solutions and get a walk through of the platform and analysis, get in touch here.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022